Three Republican state attorneys general have filed a federal lawsuit to overturn the Trump administration's April decision to move state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act - a legal challenge that, if successful, would reverse one of the most significant shifts in federal cannabis policy in decades. The attorneys general of Indiana, Nebraska, and Louisiana filed their petition with the United States Court of Appeals for the District of Columbia Circuit, arguing the action by Acting Attorney General Todd Blanche was procedurally defective, exceeded statutory authority, and was arbitrary and capricious under the Administrative Procedure Act. Their suit has since been consolidated with an earlier challenge filed by prohibitionist group Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association.
What the Rescheduling Order Actually Did - and What's Now at Stake
Blanche's April order was narrow but consequential. Under its terms, marijuana products regulated under a state medical cannabis license immediately moved to Schedule III, as would any products later approved by the FDA. A broader administrative hearing scheduled for June was set to take up adult-use rescheduling - a process that would affect a far larger share of the regulated cannabis market.
Here's the thing: Schedule III status doesn't legalize cannabis. It doesn't eliminate state licensing requirements or overhaul dispensary compliance obligations. What it does do is alter the federal tax treatment of cannabis businesses - specifically, the application of Internal Revenue Code Section 280E, which currently bars licensed cannabis operators from deducting ordinary business expenses because they handle a Schedule I or II controlled substance. A move to Schedule III would effectively remove that prohibition, freeing dispensaries, cultivators, and processors to treat rent, payroll, cost of goods, and other operating costs the same way any other retail business does. For operators running on thin margins, that matters enormously.
If the courts vacate the rescheduling order, those potential tax benefits evaporate. 280E stays in full force. State-licensed medical dispensaries - even those operating in full compliance with their state programs - remain locked out of standard business deductions. The financial pressure that's characterized cannabis retail since the earliest days of legalization doesn't ease.
The Legal Arguments and Who's Behind Them
The AGs' complaint charges that the rescheduling action "fails to comport with the requirements" of federal law, was "improperly promulgated," exceeds the Attorney General's authority under the CSA, and is ultimately arbitrary and capricious. SAM and NDASA's earlier petition makes a nearly identical argument, adding that the order violates the rulemaking requirements of the Administrative Procedure Act - a procedural law that governs how federal agencies must act when issuing regulations with the force of law.
What's striking here is who's doing the legal work. SAM announced in January that it had retained Torridon Law PLLC to fight rescheduling - a firm where former U.S. Attorney General William Barr, who helmed the DOJ during Trump's first term, is a partner. SAM and NDASA's petition was signed by Torridon attorneys. So the firm representing the most prominent opponents of federal cannabis reform is run in part by a former top law enforcement official from the same president whose current DOJ issued the rescheduling order. The irony is not subtle.
The consolidated suits name as defendants the DOJ, the DEA, Acting AG Blanche, and DEA Administrator Terrance Cole. The court joined the two petitions on May 27.
Congressional Pressure Is Also Building
The lawsuit isn't the only front. A House committee voted earlier in May to block federal officials from taking further steps to carry out cannabis rescheduling - a move that, if it advances through the full legislative process, could effectively freeze the administrative hearing on adult-use products before it produces any outcome.
Separately, a federal judge dismissed a different SAM lawsuit in late May - one that had targeted a Trump administration initiative to allow Medicare patients to use benefits for hemp-derived products. That loss didn't slow SAM's broader legal push; the organization's CEO characterized the AG lawsuit as part of a growing coalition determined to reverse what it called a dangerous and illegal order.
For cannabis operators, the political picture is more complicated than it looked in April. The rescheduling order came from a Republican DOJ. The lawsuit opposing it was filed by Republican AGs. The congressional move to block further action came from a House committee controlled by the same party. The industry is watching a fight unfold inside Republican politics over federal cannabis policy - and the outcome will shape the operating environment for every licensed business in the country.
What Operators and Compliance Teams Should Watch
In practice, the April rescheduling order has already altered the compliance calculus for some operators. State-licensed medical programs began operating on the assumption that Schedule III status applied to their products. If courts vacate the order, those assumptions unwind. That's not a hypothetical compliance risk - it's a reason for dispensary operators, multi-state operators with exposure in medical markets, and their accounting and legal teams to track this litigation closely.
A few specific pressure points worth monitoring:
- 280E tax exposure: Any tax planning that assumed rescheduling would reduce federal liability should be reviewed against the litigation timeline.
- The June administrative hearing: If the consolidated lawsuits result in a stay or the court acts quickly, the broader adult-use rescheduling process could be disrupted before the hearing concludes.
- Congressional action: A floor vote to block rescheduling would add legislative weight to the legal challenge and could effectively moot the administrative process entirely.
- State medical program operations: Nothing in the litigation directly alters state licensing, testing, packaging, or point-of-sale compliance requirements - those obligations continue regardless of how federal scheduling resolves.
Federal scheduling status has never determined whether a dispensary's seed-to-sale tracking logs need to be current, whether product batches need certificates of analysis before hitting the sales floor, or whether age verification protocols need to hold. Those are state-level compliance obligations that don't move with federal policy. What rescheduling does - or doesn't - affect is the federal tax and banking environment that shapes whether the business model is financially viable at all.
To put it plainly: the lawsuit doesn't change how a licensed dispensary operates today. It does determine whether the regulatory environment those operators have been building toward becomes more sustainable - or stays exactly as difficult as it has always been.
